BU
BUGLF.US BluGlass Limited
- Market cap
- USD 21.2M
- P/E
- -
- P/B
- 2.14x
- ROE
- -74.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is BUGLF.US undervalued?
Graham numberThe Graham number of BluGlass Limited cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
BluGlass Limited fundamental analysis
No fundamental analysis for BluGlass Limited yet.
BluGlass Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About BluGlass Limited
BluGlass Limited, together with its subsidiaries, provides semiconductor manufacturing technology and devices for biotech, defense, quantum, consumer electronic sectors in Australia and the United States. It develops and commercialisation low temperature, remote plasma chemical vapour deposition, and gallium nitride (GaN) laser portfolio, as well as provides foundry-contract services. The company was founded in 2005 and is headquartered in Silverwater, Australia.
Full company profileBluGlass Limited financial statements
BluGlass Limited annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 685K | 714K | 425K | 656K | 364K | 605K | 1.15M | 4.62M | 5.45M | 4.21M |
| Gross Profit | -212K | -444K | -1.32M | -6.59M | -7.94M | -10.2M | -11.8M | 2.55M | 2.28M | -9.49M |
| Operating Income | -3.57M | -3.82M | -5.83M | -9.06M | -10.2M | -12.9M | -19.9M | -8.81M | -9.13M | -16.8M |
| EBITDA | -5.30M | -3.63M | -5.65M | -7.79M | -7.42M | -10.2M | -7.50M | -6.63M | -6.92M | -13.9M |
| Net Income | -3.66M | -3.84M | -14.4M | -5.99M | -6.30M | -9.36M | -11.8M | -10.1M | -7.22M | -10.8M |
| EPS | -0.01 | -0.01 | -0.03 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | 0.00 | -0.08 |
| Balance Sheet | ||||||||||
| Total Assets | 19.9M | 26.7M | 14.0M | 16.4M | 13.6M | 20.5M | 21.7M | 23.1M | 15.7M | 27.4M |
| Total Liabilities | 1.21M | 1.28M | 2.31M | 4.04M | 6.05M | 7.24M | 7.81M | 8.25M | 12.3M | 13.0M |
| Shareholders' Equity | 18.7M | 25.4M | 11.6M | 12.4M | 7.51M | 13.2M | 13.9M | 14.9M | 7.62M | 14.4M |
| Cash & Short-term Investments | 8.51M | 15.4M | 6.12M | 5.43M | 4.18M | 5.35M | 4.26M | 5.57M | 3.77M | 11.3M |
| Total Debt | - | - | - | 1.72M | 3.51M | 4.63M | 4.49M | 4.68M | 7.10M | 8.05M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -2.60M | -3.51M | -4.93M | -4.36M | -4.81M | -6.26M | -11.9M | -6.95M | -4.16M | -8.87M |
| Capital Expenditure | 37.0K | 114K | 4.31M | 1.68M | 90.1K | 4.28M | 599K | 1.47M | 1.81M | 1.26M |
| Free Cash Flow | -2.63M | -3.63M | -9.24M | -6.04M | -4.90M | -10.5M | -12.5M | -8.42M | -7.96M | -10.1M |
| Ratios | ||||||||||
| ROE | -19.6% | -15.1% | -123.9% | -48.4% | -83.9% | -70.8% | -84.6% | -68.1% | -94.7% | -74.8% |
| ROA | -18.4% | -14.4% | -103.4% | -36.5% | -46.5% | -45.7% | -54.2% | -43.8% | -45.9% | -39.3% |
| Net Profit Margin | -534.5% | -538.0% | -3,396.7% | -914.0% | -1,732.4% | -1,547.0% | -1,025.2% | -219.5% | -132.4% | -255.9% |
| Debt to Equity | - | - | - | 0.14x | 0.47x | 0.35x | 0.32x | 0.31x | 0.93x | 0.56x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
BluGlass Limited dividends
BluGlass Limited has not paid dividends in the last 10 fiscal years.
Last stock split: 1:20 on Nov 26, 2025.
Who owns BluGlass Limited
- Insiders 24.69%
- Institutions 1.04%
- Public & others 74.27%
- Shares outstanding 193M
- Free float 150M
BluGlass Limited company profile
- Company name
- BluGlass Limited
- Ticker
- BUGLF.US
- Exchange
- USA Stocks
- Sector
- Technology
- Industry
- Semiconductors & Semiconductor Equipment
- Fiscal year end
- June
- Address
- 74 Asquith Street, Silverwater, NSW, Australia, 2128
- Phone
- 61 2 9334 2300
- Website
- bluglass.com
About BluGlass Limited
BluGlass Limited, together with its subsidiaries, provides semiconductor manufacturing technology and devices for biotech, defense, quantum, consumer electronic sectors in Australia and the United States. It develops and commercialisation low temperature, remote plasma chemical vapour deposition, and gallium nitride (GaN) laser portfolio, as well as provides foundry-contract services. The company was founded in 2005 and is headquartered in Silverwater, Australia.
BluGlass Limited management
8- Mr. Omer GranitExecutive Chair · born 1976
- Mr. James Haden BEEMD, CEO, President & Executive Director
- Mr. Samuel Samhan BEC, M.B.A.Chief Financial Officer
- Dr. Ian Mann M.B.A., Ph.D.Chief Technology & Operations Officer
- Mr. Brad SiskavichExecutive Vice President
- Dr. Josh Brown Ph.D.Head of Epitaxy
- Mr. Denis TimoneyHead of Hardware & Facilities
- Mr. Andrew Palfreyman J.D.Company Secretary